ANI Pharmaceuticals, Inc.
ANIP
$70.10
-$0.14-0.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 266.04M | 237.46M | 247.06M | 227.81M | 211.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 266.04M | 237.46M | 247.06M | 227.81M | 211.37M |
| Cost of Revenue | 100.16M | 93.58M | 100.27M | 93.39M | 74.62M |
| Gross Profit | 165.89M | 143.88M | 146.79M | 134.42M | 136.76M |
| SG&A Expenses | 91.66M | 73.66M | 82.29M | 76.26M | 81.77M |
| Depreciation & Amortization | 19.64M | 20.92M | 22.61M | 22.63M | 23.28M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 226.21M | 198.76M | 217.43M | 204.58M | 196.20M |
| Operating Income | 39.84M | 38.71M | 29.63M | 23.23M | 15.17M |
| Income Before Tax | 37.10M | 40.22M | 31.48M | 33.80M | 10.53M |
| Income Tax Expenses | 12.39M | 10.73M | 3.99M | 7.18M | 1.98M |
| Earnings from Continuing Operations | 24.71M | 29.49M | 27.49M | 26.62M | 8.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.71M | 29.49M | 27.49M | 26.62M | 8.55M |
| EBIT | 39.84M | 38.71M | 29.63M | 23.23M | 15.17M |
| EBITDA | 59.48M | 59.63M | 52.24M | 45.86M | 38.45M |
| EPS Basic | 1.09 | 1.31 | 1.23 | 1.19 | 0.37 |
| Normalized Basic EPS | 1.06 | 1.02 | 0.79 | 0.55 | 0.36 |
| EPS Diluted | 1.05 | 1.28 | 1.17 | 1.13 | 0.36 |
| Normalized Diluted EPS | 1.02 | 0.99 | 0.75 | 0.52 | 0.35 |
| Average Basic Shares Outstanding | 21.16M | 20.91M | 20.69M | 20.07M | 19.83M |
| Average Diluted Shares Outstanding | 21.92M | 21.54M | 21.77M | 21.09M | 20.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.00% | 1.29% | 4.76% |